Health News

Stay informed with the latest health industry news from around the globe. Read about advancements in health technology, updates in health insurance, innovations in medical devices, and more. Keep up with important health trends and industry developments.

Jun 6, 2026 at 4:45 PM

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the presentation of new data from its CATALYST and MOMENTUM trials at the American Diabetes Association’s 86th Scientific Sessions. The presentations underscore the critical role of...
Jun 6, 2026 at 2:45 PM

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...
Jun 6, 2026 at 9:00 AM

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF’3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, during a late-breaking expert symposium at the 86th Scientific Sessions of the American Diabetes Association (ADA). The objectives for the Phase 2 studies were to identify the right doses for Phase 3 and to test escalation schemes. Across both weekly and monthl...
Jun 6, 2026 at 7:00 AM

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

ACTON, Mass.--(BUSINESS WIRE)--Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort...
Jun 5, 2026 at 7:32 PM

Tidepool Showcases New Real-World Clinical Data and Landmark Women’s Health Initiative at ADA 2026

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool, the nonprofit leader advancing innovation in diabetes technology, today unveiled new clinical insights and research initiatives in conjunction with the American Diabetes Association’s (ADA) 86th Scientific Sessions. The company’s presentation slate focuses on the immediate utility of real-world data and Tidepool’s ongoing commitment to closing gaps in women’s health research. Today’s insights demonstrate sustained progress in the adoption of accessi...
Jun 5, 2026 at 7:30 PM

OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

MENLO PARK, Calif.--(BUSINESS WIRE)--At ADA 2026, OrsoBio to share clinical and preclinical data highlighting potential multi-system benefits of mitochondrial protonophore mechanism....
Jun 5, 2026 at 7:30 PM

Verdiva Bio Presents Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva Bio” or “the Company”), a clinical-stage biotechnology company advancing a scalable, once-weekly oral obesity product pipeline, today announced new preclinical data for VRB-103, a once-weekly oral amylin receptor-selective amylin analog, and VRB-104, a unimolecular amylin and GLP-1 receptor dual agonist. These data are being presented in poster sessions at the 86th Scientific Sessions of the American Diabetes Association (AD...
Jun 5, 2026 at 5:43 PM

Heard Partners with CAMFT to Bring Therapist-Specific Financial Support to California's Marriage and Family Therapists

SEATTLE--(BUSINESS WIRE)--Heard, the financial platform built for therapists in private practice, has partnered with the California Association of Marriage and Family Therapists (CAMFT) to give California's LMFTs specialized support for the business side of their practice. Running a private practice means holding two roles at once: clinician and business owner. Most LMFTs are trained for the first and figure out the second along the way, and that friction has a cost. Research in behavioral econ...
Jun 5, 2026 at 5:38 PM

New Study Reveals the True Environmental Impact of Periodontal Disease – And What You Can Do About It

GENEVA--(BUSINESS WIRE)--Today P&G Oral Care announces the release of a new, first-of-its kind LCA study published in the Journal of Dentistry finds managing advanced periodontal disease can be associated with up to ~10× higher environmental impact compared with maintaining periodontal health through at-home prevention. The peer-reviewed paper, titled “Quantifying the Environmental Impact Potential from Periodontal Health to Disease: Findings from a Life Cycle Assessment Study,” for the fir...
Jun 5, 2026 at 4:35 PM

AM Best Affirms Credit Ratings of CVS Health Corporation’s Aetna Inc. Subsidiaries

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a” (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of its ultimate parent, CVS Health Corporation (CVS Health) (NYSE: CVS). (Please see below for a detailed listing of the compani...
Turn Your News Into Headlines
Submit Your Release

Get Story Ideas Delivered to Your Inbox

Sign Up